We are live on ! Find out more

SPHS

Sophiris Bio, Inc.

SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

21 hedge funds and large institutions have $18.2M invested in Sophiris Bio, Inc. in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New

Increased

Maintained

Reduced

Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

28% more capital invested

Capital invested by funds: $14.3M → $18.2M (+$3.93M)

17% more funds holding

Funds holding: 18 → 21 (+3)

Holders

Holders Change

Holders Change %

+16.67%

% of All Funds

0.61%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

Rank	Fund	Capital Flow
1	GCM Gruss Capital Management New York	+$1.03M
2	U UBS Zurich, Switzerland	+$5.99K
3	Bank of New York Mellon New York	+$5.63K
4	Wells Fargo San Francisco, California	+$5.07K
5	Citigroup New York	+$2.9K

Top Sellers

Rank	Fund	Capital Flow
1	First Manhattan New York	-$708K
2	Franklin Resources San Mateo, California	-$412K
3	SC Sophrosyne Capital New York	-$211K
4	T. Rowe Price Associates Baltimore, Maryland	-$9.57K
5	Morgan Stanley New York	-$560

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	1 T. Rowe Price Associates Baltimore, Maryland	$4.72M	-$9.57K	-3,400	-0.2%
2	GPP 2 Great Point Partners Greenwich, Connecticut	$4.65M	–	–	–
3	AG 3 Artal Group Luxembourg	$2.93M	–	–	–
4	BI 4 BVF Inc San Francisco, California	$1.76M	–	–	–
5	GCM 5 Gruss Capital Management New York	$1.07M	+$1.03M	+364,215	New
6	6 First Manhattan New York	$1.04M	-$708K	-251,456	-42%
7	PAI 7 Palo Alto Investors Palo Alto, California	$858K	–	–	–
8	8 First Eagle Investment Management New York	$733K	–	–	–
9	9 Deutsche Bank Frankfurt Am Main Ge, Germany	$216K	–	–	–
10	10 TD Asset Management Toronto, Ontario, Canada	$172K	–	–	–
11	11 Bank of New York Mellon New York	$42K	+$5.63K	+2,000	+16%
12	BIM 12 BlackRock Investment Management Wilmington, Delaware	$7K	+$2.67K	+949	+63%
13	U 13 UBS Zurich, Switzerland	$6K	+$5.99K	+2,128	New
14	14 Bank of Montreal Toronto, Ontario, Canada	$5K	–	–	–
15	15 Wells Fargo San Francisco, California	$5K	+$5.07K	+1,800	New
16	16 Citigroup New York	$3K	+$2.9K	+1,031	New
17	17 Royal Bank of Canada Toronto, Ontario, Canada	$2K	+$270	+96	+13%
18	TRCT 18 Tower Research Capital (TRC) New York	$1K	+$1.13K	+401	+401%
19	19 Franklin Resources San Mateo, California	–	-$412K	-184,100	Closed
20	SC 20 Sophrosyne Capital New York	–	-$211K	-93,900	Closed
21	21 Morgan Stanley New York	–	-$560	-199	-88%
22	22 Barclays London, United Kingdom	–	+$352	+125	New

SPHS Hedge Fund Activity: Q3 2014 in Review

21 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q3 2014, worth a combined $18.2M — up 28% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SPHS positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Gruss Capital Management, opening a new position worth an estimated $1.03M. The largest seller was First Manhattan, cutting an estimated $708K.

21 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q3 2014, up from 18 in Q2 2014.
Funds reported $18.2M of Sophiris Bio, Inc. stock for Q3 2014, up 28% quarter-over-quarter.
5 funds opened new Sophiris Bio, Inc. positions in Q3 2014 and 2 closed out, a net change of +3 holders.
The largest Sophiris Bio, Inc. buyer in Q3 2014 was Gruss Capital Management, an estimated $1.03M added.
The largest Sophiris Bio, Inc. seller in Q3 2014 was First Manhattan, an estimated $708K sold.

Based on aggregated 13F filings for Q3 2014.

Sophiris Bio, Inc. SPHS